3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Gynecologic
2
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Urinary Bladder Neoplasms
41
Prostatic Neoplasms
32
Ovarian Neoplasms
23
Testicular Neoplasms
18
Carcinoma, Transitional Cell
16
Carcinoma, Renal Cell
16
Carcinoma, Non-Small-Cell Lung
15
Neoplasms
13
Melanoma
13
Testicular Germ Cell Tumor
12
Colorectal Neoplasms
12
Breast Neoplasms
12
Neoplasm Metastasis
10
Urethral Neoplasms
9
Stomach Neoplasms
9
Lung Neoplasms
9
Endodermal Sinus Tumor
9
Teratoma
8
Pancreatic Neoplasms
8
Central Nervous System Neoplasms
8
Carcinoma, Embryonal
8
Carcinoma, Ovarian Epithelial
7
Triple Negative Breast Neoplasms
6
Seminoma
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Esophageal Neoplasms
5
Endometrial Neoplasms
5
Penile Neoplasms
4
Interventions
pembrolizumab
3
Trastuzumab
2
Nivolumab
2
tucatinib
1
regorafenib
1
pertuzumab
1
niraparib
1
milademetan
1
dostarlimab
1
cobimetinib
1
brigimadlin
1
atezolizumab
1
alectinib
1
Vemurafenib
1
Tomography, X-Ray Computed
1
Ramucirumab
1
Radiation
1
Positron-Emission Tomography
1
Paclitaxel
1
Magnetic Resonance Imaging
1
HhAntag691
1
Fulvestrant
1
Erlotinib Hydrochloride
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Brachytherapy
1
Antibodies
1
AZD9833
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Paclitaxel
×
Genitourinary
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled